Author: Ken Dropiewski

Windtree Therapeutics Announces Pricing of $20.0 Million Public Offering and Uplisting to the Nasdaq Capital Market

WARRINGTON, Pa., May 20, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced the pricing of its public offering of 2,758,620 units at a price to the public of $7.25 per […]

Ra Medical Systems Announces Pricing of $10.0 Million Public Offering

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (“Ra Medical”) (NYSE: RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, today announced that it has priced a public offering of an aggregate of 22,222,222 shares of common […]

Thermedical’s Groundbreaking SERF Ablation System Earns FDA’s Breakthrough Device Designation

WALTHAM, Mass.–(BUSINESS WIRE)–Thermedical®, a developer of thermal-ablation medical systems to treat ventricular tachycardia (VT), today announced that it has received Breakthrough Device Designation from the U.S. Food & Drug Administration (FDA) for its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate® catheter. The FDA Breakthrough Devices Program is intended to help patients […]

Cathvision Completes New Investment Round of a Total 13M Euro

COPENHAGEN, May 19, 2020 /PRNewswire/ — CathVision ApS, a medical device company developing a novel artificial intelligence therapeutic platform for cardiac electrophysiology procedures, has completed an investment round of a total 13M euro. Both existing and new investors participated in the round. The proceeds allow the company to begin multi-center clinical studies and complete […]

Mentice Launches Seventh Generation Platform Aimed to Transform Endovascular Therapy

VIST® G7 Brings Reality to Complex Interventions and Introduces a Scalable and Flexible Platform for Advanced Future Applications GOTHENBURG, Sweden, May 19, 2020 /PRNewswire/ — Mentice AB (STO: MNTC), today announced the global introduction of its seventh-generation simulation platform – VIST® G7 to become the endovascular simulation platform for Mentice solutions including […]

Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results and Announces AGM Results

VANCOUVER, British Columbia, May 19, 2020 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended March 31, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). “Since the outbreak of […]

PROTECT III Study Shows Placing Impella Prior to High-Risk PCI is Associated with Lower Mortality Compared to Bailout PCI

Women Disproportionately Impacted with Bailout DANVERS, Mass.–(BUSINESS WIRE)–Data from more than 1,000 patients presented during the virtual 2020 Society for Cardiovascular Angiography & Interventions (SCAI) Scientific Sessions demonstrates Impella reduced in-hospital mortality when placed before a non-emergent percutaneous coronary intervention (PCI) is performed. As detailed in the online presentation, the research found, in […]

Mezzion Pharma’s new orphan drug udenafil improved ventricular function measured by myocardial performance index (MPI) in adolescents with congenital single ventricle heart disease (SVHD) – Further results from the pivotal 400-subject Phase 3 FUEL Trial

Mezzion Pharma files new patent applications to cover globally this important MPI advancement, a unique new finding as a result of treatment of SVHD patients with udenafil SEOUL, South Korea, May 18, 2020 /PRNewswire/ — Mezzion Pharma Co. Ltd. today announced that analysis of data from its Phase 3 FUEL trial showed statistically significant positive […]

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-Free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

Multicenter, International ALPS Registry Outcomes Just Published in Journal of Endovascular Therapy PARIS–(BUSINESS WIRE)–LimFlow SA, a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease (PAD), today announced publication of positive two-year data from the ALPS Registry of […]